Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

January 28, 2026

Study Completion Date

April 21, 2026

Conditions
Postural Orthostatic Tachycardia Syndrome (POTS)
Interventions
DRUG

REGN7544

Subcutaneous (SC) administration

DRUG

Placebo

SC administration

Trial Locations (18)

10016

RECRUITING

New York University Langone, New York

10032

RECRUITING

Columbia University, New York

33756

RECRUITING

Innovative Research of West Florida, Inc., Clearwater

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

46202

RECRUITING

Indiana University Health Neuroscience Center, Indianapolis

55905

RECRUITING

Mayo Clinic, Rochester

64111

RECRUITING

Saint Luke's MidAmerica Heart Institute, Kansas City

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

75390

RECRUITING

University of Texas Southwestern, Dallas

84108

RECRUITING

University of Utah, Salt Lake City

85297

RECRUITING

Mercy Gilbert Medical Center, Gilbert

91105

RECRUITING

Southern California Heart Specialists, Pasadena

92011

RECRUITING

North County Neurology Associates, Carlsbad

94304

RECRUITING

Stanford University, Palo Alto

06511

RECRUITING

Yale University, New Haven

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

T2N 4Z6

RECRUITING

University of Calgary, Calgary

T6G 2B3

RECRUITING

University of Alberta Hospital, Edmonton

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY